evipedia.ai
← Back

Rhodiola rosea for Health & Longevity

Evidence Review created on 11/05/2026 using AI4L / Opus 5.5

Also known as: Rhodiola, Golden Root, Arctic Root, Roseroot, Rose Root, Rosenroot, King’s Crown, Aaron’s Rod, Hong Jing Tian, Sedum rosea, SHR-5, WS 1375

Motivation

Rhodiola rosea (golden root, Arctic root) is a flowering plant of cold northern and mountain regions whose root is sold as an herbal extract. It belongs to a small group of herbs said to increase the body’s resistance to physical and mental stress, and it has become one of the most widely used of them in Europe and North America. Its interest for people pursuing long-term health lies in the promise of better stamina, steadier mood and clearer thinking under strain, without the rebound fatigue associated with stimulants.

The root has a long history in Scandinavian, Russian and Central Asian folk medicine, and Soviet-era scientists studied it intensively for soldiers, athletes and workers under heavy demands. More recently, laboratory studies of the extract’s effect on the lifespan of flies and worms drew the attention of researchers studying aging.

This review examines the human evidence on stress-related fatigue and exercise capacity, the laboratory research relevant to aging, and the safety, drug-interaction and product-quality questions that shape how the extract is used in practice.

Benefits - Risks - Protocol - Conclusion

This section lists high-level expert content and narrative reviews that discuss Rhodiola rosea in depth.

Only four items qualify. No dedicated content was found from Peter Attia or Lifespan.io (which names it only as one ingredient of a multi-ingredient product); FoundMyFitness covers it only in a short multi-supplement clip with Layne Norton, and Chris Kresser mentions it only briefly within broader articles, such as two sentences in his nootropics article (Chris Kresser nootropics article); neither meets the depth requirement.

Grokipedia

  • Rhodiola rosea

    Broad encyclopedic overview of botany, common names, constituents, traditional use and evidence, noting that most longevity, heart-protection and brain-protection claims rest on preclinical data.

Examine

ConsumerLab

  • Rhodiola Supplements Review & Top Picks

    Independent laboratory testing of rosavin and salidroside content in popular brands, with Top Picks and a January 2026 update on quality problems; detailed results are behind a membership paywall.

Systematic Reviews

This section lists the most cited and most recent systematic reviews and meta-analyses of Rhodiola rosea in humans.

No systematic review or meta-analysis focuses on the harms of Rhodiola rosea; adverse events are covered only as secondary outcomes in the efficacy reviews above.

Mechanism of Action

The root contains about 140 compounds; the quality markers are salidroside (a sugar-bound phenol found across the genus) and the rosavins (specific to R. rosea) (narrative review, Panossian 2010). Proposed mechanisms:

  • Stress-hormone modulation: extracts are reported to damp the hypothalamic-pituitary-adrenal (HPA) axis (the brain-to-adrenal system that releases cortisol); one trial co-authored by a Swedish Herbal Institute scientist found a lower cortisol response to waking (Olsson 2009).
  • Cellular stress defenses: a narrative review describes induction of heat shock protein 70 (Hsp70, a protein that repairs misfolded proteins), and effects on c-Jun N-terminal kinase (JNK, a stress-signaling enzyme), nitric oxide and FoxO/DAF-16 (a stress-resistance gene switch) (Panossian 2010).
  • Monoamines: root extracts inhibit monoamine oxidase A and B (MAO-A/B, enzymes that break down serotonin, dopamine and noradrenaline) in cell-free assays (van Diermen 2009).
  • Longevity pathways: worm lifespan extension required DAF-16 and SKN-1 (an antioxidant-defense regulator) (Jiang 2021), whereas fly lifespan extension persisted when sirtuin (aging-linked regulator enzymes), insulin-signaling or TOR (target of rapamycin, a nutrient-sensing growth regulator) pathways were genetically altered (Schriner 2013).

A review offers a competing reading, hormesis (low doses protective, high doses not) (Calabrese 2023). Pharmacology: human half-life is unmeasured; intravenous salidroside in rats has a half-life near one hour, distributes to muscle and is cleared mainly by the kidneys (Zhang 2013). In humans, a commercial extract modestly inhibited CYP2C9 (a liver enzyme clearing warfarin and losartan) but not CYP1A2, CYP2C19, CYP2D6 or CYP3A4 (other drug-metabolizing liver enzymes) (Thu 2016).

Historical Context & Evolution

Rhodiola rosea was originally a folk remedy of Scandinavia, Russia, Siberia and Central Asia, used against fatigue, cold, altitude, infection and low mood, and it gained official medicinal registration in Russia and Sweden in the twentieth century, according to a narrative review (Panossian 2010).

It came to be considered for health optimization through Soviet research on “adaptogens” (herbs thought to raise non-specific resistance to stress), which focused on soldiers, athletes and workers. From 2000 onward, Swedish Herbal Institute scientists co-authored placebo-controlled trials of the institute’s SHR-5 extract that reported less fatigue in physicians on night duty, students and cadets, and less depression (Darbinyan 2000; Spasov 2000; Shevtsov 2003; Darbinyan 2007).

Western systematic reviews in 2011 and 2012 found these positive results promising but unreplicated and at risk of bias (Hung 2011; Ishaque 2012). Independent trials then reported a null result for depression (Mao 2015) and worse fatigue than placebo in shift-working students (Punja 2014), while European regulators (European Medicines Agency, EMA) accepted stress-related fatigue on the basis of traditional use rather than trial proof (EMA herbal summary).

Longevity interest began when University of California, Irvine researchers reported longer fruit-fly lifespan (Jafari 2007). Recent meta-analyses disagree on endurance (Wang 2025; Mou 2026), so the field remains open rather than settled in either direction.

Expected Benefits

High 🟩 🟩 🟩

Improved Endurance Exercise Performance ⚠️ Conflicted

A dose one hour before exercise lengthened time to exhaustion in a Leuven trial (De Bock 2004) and shortened a cycling time trial at Gettysburg (Noreen 2013). A meta-analysis of 26 trials in 668 healthy participants aged 11–45 found gains in VO2max (maximal oxygen uptake, a key aerobic-fitness measure) and time to exhaustion (Wang 2025). A 2026 meta-analysis found no VO2max effect (Mou 2026), and 30 days of 600 mg/day did not change marathon time (Shanely 2014). Net reading: a small acute effect is likely; chronic benefit is unproven.

Magnitude: VO2max standardized mean difference (SMD, effect in standard-deviation units; a standard deviation is the typical spread of individual values around the group average) 0.32 (95% CI, confidence interval, the range likely to contain the true effect: 0.12 to 0.52) and time to exhaustion SMD 0.38 (95% CI 0.07 to 0.69) versus placebo or control (Wang 2025); time to exhaustion 0.4 minutes longer than placebo (17.2 versus 16.8 minutes) (De Bock 2004).

Medium 🟩 🟩

Placebo-controlled SHR-5 trials reported less fatigue and better attention in night-duty physicians (Darbinyan 2000), students (Spasov 2000), cadets (Shevtsov 2003) and burnout patients (Olsson 2009), all co-authored by Swedish Herbal Institute staff; an institute-sponsored three-herb combination shortened fatigue in long COVID (persisting coronavirus disease 2019 symptoms) (Karosanidze 2022). A systematic review rated these trials at high or unclear bias risk (Ishaque 2012). An independent 42-day trial in shift-working students found fatigue worse than placebo (Punja 2014). Net reading: a short-term anti-fatigue effect is plausible but rests on unreplicated manufacturer-linked trials.

Magnitude: Anti-fatigue index 0.13 (two capsules) and 0.11 (three capsules) higher than placebo (1.0385 and 1.0195 versus 0.9046), p (probability the difference arose by chance) < 0.001, no confidence interval reported (Shevtsov 2003); contrary trial: vitality score change −17.3 points versus placebo (95% CI −30.6 to −3.9), favoring placebo (Punja 2014).

Relief of Mild to Moderate Depression ⚠️ Conflicted

In a 6-week trial of 89 patients, 340 or 680 mg/day of SHR-5 improved Hamilton Depression Rating Scale (HAM-D, a clinician-rated depression score) results while placebo did not; a Swedish Herbal Institute scientist co-authored it (Darbinyan 2007). An independent, publicly funded 12-week trial in 57 patients found no significant difference from placebo, and sertraline (a prescription antidepressant) also did not separate (Mao 2015). Net reading: any antidepressant effect is modest and inconsistently reproduced.

Magnitude: HAM-D fell 5.1 points (95% CI −8.8 to −1.3) on R. rosea versus 4.6 points (95% CI −8.6 to −0.6) on placebo, difference not significant (p = 0.79); odds ratio (OR, how much likelier improvement was than on placebo) 1.39 (95% CI 0.38 to 5.04) (Mao 2015).

Reduced Life-Stress and Anxiety Symptoms

In a Schwabe-funded trial, 80 mildly anxious adults randomized to 400 mg/day of Schwabe’s extract (Vitano) or no treatment improved in anxiety, stress and mood over 14 days relative to controls, without placebo or blinding (Cropley 2015). Open-label studies (participants knew what they took) of WS 1375 with Schwabe co-authors, in life stress (Edwards 2012) and burnout (Kasper 2017), and a 10-patient pilot in generalized anxiety disorder (Bystritsky 2008), reported improvement without comparison groups. No placebo-controlled anxiety trial has been published.

Magnitude: Perceived Stress Questionnaire “tension” subscore fell 2.4 points (standard deviation 2.6) over 12 weeks, no control group (Kasper 2017).

Low 🟩

Better Cardiac Function in Established Heart Disease

Meta-analysis of 25 Chinese trials found an intravenous R. rosea injection raised ejection fraction (share of blood pumped per beat) in weak-pumping heart failure (Du 2025); another found mixed Rhodiola formulations eased angina (chest pain from poor heart blood flow) (Yu 2014). Evidence is indirect: injection, other species, add-on use.

Magnitude: Left ventricular ejection fraction 6.81 percentage points higher than control (95% CI 5.71 to 7.91) (Du 2025); angina symptom improvement OR 2.40 (95% CI 1.57 to 3.66) (Yu 2014).

Improved Lung Function in Chronic Lung Disease

A meta-analysis of nine trials in chronic obstructive pulmonary disease (COPD, a progressive airflow-limiting lung disease) found better lung function and blood oxygen with Rhodiola than placebo (Yu 2023). Evidence is indirect: the trials tested R. crenulata, R. kirilowii and R. wallichiana, not R. rosea.

Magnitude: FEV1 % predicted (air exhaled in one second relative to expected) 9.28 points higher than placebo (95% CI 4.41 to 14.15) (Yu 2023).

Better High-Altitude Tolerance ⚠️ Conflicted

Meta-analyses found the related species R. crenulata raised blood oxygen in altitude illness (Gao 2025) and Rhodiola eased symptoms after descent (Mou 2026). A crossover trial (each participant took both treatments in turn) found no prevention of acute mountain sickness versus placebo (Chiu 2013). Net reading: no reliable preventive effect.

Magnitude: Acute mountain sickness incidence 60.8% on R. crenulata and 60.8% on placebo; adjusted OR 1.02 (95% CI 0.69 to 1.52) (Chiu 2013).

Speculative 🟨

Lifespan Extension

Extracts lengthened lifespan in fruit flies (Jafari 2007; Schriner 2013), worms (Jiang 2021) and yeast (Bayliak 2011), and salidroside in a short-lived fish (Wang 2018). Basis is animal data only.

Neuroprotection and Memory in Aging

A meta-analysis of 36 rodent studies found better learning and memory (Ma 2018). No human trial has tested prevention of cognitive decline; basis is animal data only.

Delayed Cellular Senescence

Salidroside delayed senescence (permanent growth arrest) of human fibroblasts (connective-tissue cells) by boosting mitochondrial production through SIRT1 (an aging-related regulator enzyme) (Mao 2019). Basis is cell studies only.

Higher Antioxidant Capacity

Meta-analyses report higher total antioxidant capacity, an unvalidated blood marker (Wang 2025; Mou 2026). No clinical outcome has been linked to this change; basis is biomarker data only.

Reduced Exercise-Induced Muscle Damage ⚠️ Conflicted

A meta-analysis found lower post-exercise creatine kinase (CK, a muscle-damage marker) (Wang 2025); a marathon trial found no change (Shanely 2014). Basis is biomarker data only. Net reading: no demonstrated recovery benefit.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has linked gene variants to benefit. CYP2C9 status changed the extract’s effect on drug clearance (Thu 2016), but whether variants alter the extract’s own exposure is unknown.
  • Baseline biomarkers and symptom load: No baseline laboratory value is known to predict benefit; positive trials selected people under acute strain (night duty, exams, burnout), and in burnout the waking cortisol response changed with treatment (Olsson 2009). Benefit in unstressed adults is less documented.
  • Training status: In endurance meta-analysis subgroups, trained individuals showed larger reductions in CK, and doses above 600 mg/day larger VO2max gains (Wang 2025).
  • Sex: Human trials did not analyze sex differences; participants in a systematic review of sports trials were about three-quarters male (Sanz-Barrio 2023). In flies, effects on gene expression and heat-stress protection differed by sex (Schriner 2013).
  • Pre-existing conditions: Burnout, mild depression and generalized anxiety are the conditions most studied; heart failure and lung-disease data come from other preparations or species, per two meta-analyses (Du 2025; Yu 2023).
  • Age: Trials enrolled adults aged 18–70 (Darbinyan 2007); an endurance meta-analysis reported a mean age of 22 years, ages 11–45 (Wang 2025); no trial targeted adults over 70, so benefit at the older end of the target range is untested.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event data come from small trials of 12 weeks or less, and no harm has been shown with a clinical endpoint by more than one independent research group.

Medium 🟥 🟥

Mild Adverse Events ⚠️ Conflicted

Drug references list dizziness, dry mouth or excess saliva, and rare allergic reactions (WebMD Rhodiola monograph); dizziness and dry mouth were most common in an uncontrolled anxiety pilot (Bystritsky 2008). In an independent 12-week trial, adverse events were more frequent than on placebo but less frequent than on sertraline (Mao 2015), whereas a 42-day trial found no difference from placebo (Punja 2014). Net reading: mild, reversible events at rates near or modestly above placebo.

Magnitude: Participants reporting any adverse event: 30.0% on R. rosea, 16.7% on placebo and 63.2% on sertraline, three-group p = 0.012 (Mao 2015).

Low 🟥

Reduced CYP2C9 Drug Clearance

In 13 healthy volunteers, 14 days of Arctic Root extract reduced CYP2C9 activity, most in normal metabolizers (Thu 2016). Evidence is indirect: a drug-level marker; warfarin bleeding or phenytoin toxicity is inferred. Losartan exposure nearly doubled in rabbits (Spanakis 2013) but warfarin was unaffected in manufacturer-run rat work (Panossian 2009).

Magnitude: Metabolite-to-losartan ratio 21% lower after pretreatment than without it (p = 0.023), indicating reduced CYP2C9 activity; no clinical outcome measured (Thu 2016).

Serotonergic or Heart-Rhythm Reaction With Antidepressants

Case reports describe restlessness, tremor and sweating suggesting serotonin syndrome (excess serotonin activity) in a woman on paroxetine (Maniscalco 2015; erratum Maniscalco 2023 corrected only the plant name), and a fast heart rhythm with an SSRI (a common antidepressant class) (McGovern 2010). Monoamine oxidase inhibition is the inferred mechanism.

Magnitude: Not quantified in available studies. Only two case reports exist, so no incidence can be estimated.

Mania, Overstimulation or Insomnia ⚠️ Conflicted

A 58-year-old man developed mania needing 36 hours of intubation (a breathing tube) after triple-dose R. rosea (Whig 2022); a review found no earlier cases (Bostock 2018). Insomnia, inferred from monoamine oxidase inhibition (van Diermen 2009), improved on extract, not placebo, in depression (Darbinyan 2007). Net reading: insomnia is unconfirmed.

Magnitude: Not quantified in available studies. Only a single case report of mania exists, so no incidence can be estimated.

Perioperative Bleeding

A 37-year-old woman who had stopped long-term R. rosea one week before liposuction bled excessively, returned with low blood pressure and needed a transfusion; clotting tests showed platelet dysfunction (impaired blood-clotting cells) (Serna-Muñoz 2026). The authors attribute it to salidroside’s platelet-inhibiting effect; causation is unproven.

Magnitude: Not quantified in available studies. Only a single case report of bleeding exists, so no incidence can be estimated.

Speculative 🟨

Product Adulteration and Contamination

One-fifth of 40 European products labeled R. rosea lacked rosavin (Booker 2016, one Schwabe co-author); one US product appeared salidroside-spiked, and all seven had trace metals (Porwollik 2026). Basis is product testing; no harm documented.

Loss of Benefit at High Doses

A review reports hormetic dose curves for rhodiola and salidroside, with high concentrations losing benefit (Calabrese 2023); in yeast, extract reduced oxidative-stress resistance in growing cells (Bayliak 2011). Basis is cell and model-organism data only.

Risk-Modifying Factors

  • Genetic polymorphisms: CYP2C9 inhibition was more pronounced in extensive (normal) metabolizers than in intermediate and poor metabolizers (Thu 2016), so interaction risk with warfarin or phenytoin may be greatest in people with normal CYP2C9 function.
  • Baseline biomarkers: People on warfarin with an unstable INR (international normalized ratio, a clotting-time measure) would carry the most risk from any CYP2C9 change, inferred from the inhibition seen in volunteers (Thu 2016); no baseline marker is known to predict adverse events.
  • Sex: No sex differences in adverse events have been reported; trials did not analyze them. Pregnancy and breastfeeding safety is unknown (WebMD Rhodiola monograph).
  • Pre-existing conditions: Depression treated with serotonergic antidepressants (Maniscalco 2015), bipolar disorder (inferred), and conditions managed with narrow-margin CYP2C9 drugs such as epilepsy on phenytoin raise risk.
  • Age: Older adults more often take warfarin and multiple drugs, increasing interaction exposure; trials enrolled adults up to 70 (Darbinyan 2007), and European regulators restrict use to adults over 18 (EMA herbal summary).

Key Interactions & Contraindications

Documented interactions:

  • CYP2C9 substrates (warfarin, phenytoin, losartan, glipizide, ibuprofen, celecoxib): CYP2C9 activity fell in volunteers (Thu 2016), so drug levels may rise: bleeding with warfarin, toxicity with phenytoin. INR or drug-level checks 1–2 weeks after starting or stopping are the usual safeguard.
  • Serotonergic antidepressants (paroxetine, sertraline, escitalopram, venlafaxine): Restlessness, tremor and sweating suggesting serotonin syndrome were reported with paroxetine (Maniscalco 2015). Combined use usually proceeds only with the prescriber informed, stopping at agitation, tremor or fever.
  • Sertraline (tested together): A 12-week randomized trial adding Rhodiola capsules to sertraline in 100 patients with depression reported greater improvement than sertraline alone; its abstract gives no adverse-event comparison (Gao 2020), so the serotonin-syndrome caution still applies.
  • CYP3A4 substrate midazolam: No interaction found; midazolam metabolism was unchanged after 14 days of extract (Thu 2016). Other CYP3A4 drugs, such as statins (cholesterol-lowering drugs such as atorvastatin) and calcium-channel blockers (blood-pressure drugs such as amlodipine), were not tested.
  • Over-the-counter omeprazole and dextromethorphan: No interaction found; CYP2C19 (omeprazole) and CYP2D6 (dextromethorphan) metabolism were unchanged (Thu 2016).
  • Caffeine (coffee, pre-workout supplements): No pharmacokinetic (drug-level) interaction found; CYP1A2 metabolism of caffeine was unchanged (Thu 2016). Combined use has been tested for performance in athletes (Wang 2025).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Monoamine oxidase inhibitors (selegiline, rasagiline, phenelzine, linezolid): Additive monoamine oxidase inhibition (van Diermen 2009) could raise serotonin or blood pressure; avoiding the combination is the cautious course.
  • Serotonergic supplements (St John’s wort, 5-HTP, a serotonin precursor; SAMe, S-adenosylmethionine, a mood-support supplement): Additive serotonergic activity inferred from monoamine oxidase inhibition could cause agitation or serotonin excess; introducing one agent at a time makes restlessness or tremor attributable.
  • Other adaptogens (ashwagandha, Eleutherococcus, Schisandra): Additive effects on the HPA axis are inferred and could cause overstimulation or insomnia; combination products make the dose of each herb unclear, and introducing one herb at a time makes effects attributable.
  • Prescription stimulants (modafinil, methylphenidate, amphetamine): Additive central activation inferred from monoaminergic effects could worsen insomnia, anxiety or heart rate; morning dosing with sleep and pulse monitoring limits this.
  • Sedative-hypnotics (sleep-inducing drugs: zolpidem, benzodiazepines (calming anti-anxiety drugs such as diazepam)): Opposing arousal effects inferred from monoaminergic activity could blunt sleep medication; evening dosing is avoided for this reason.
  • P-glycoprotein substrates (digoxin, dabigatran): Extracts potently inhibited P-glycoprotein (a drug-efflux transporter) in cell assays (Hellum 2010), which could raise digoxin levels (toxicity) or dabigatran levels (bleeding); drug-level or clinical checks after starting limit this.
  • Glucose-lowering drugs (metformin, insulin, glipizide): Additive glucose lowering could cause hypoglycemia (abnormally low blood sugar), as a drug reference warns (Merck Manual rhodiola monograph); blood-glucose checks after starting limit this.
  • Blood-pressure-lowering drugs (amlodipine, lisinopril, losartan): Additive blood-pressure lowering could cause hypotension (abnormally low blood pressure), as a drug reference warns (Merck Manual rhodiola monograph); blood-pressure checks after starting limit this.
  • Immunosuppressants (drugs that dampen immunity, such as tacrolimus) and anti-inflammatory drugs (ibuprofen, naproxen): A drug reference warns rhodiola may counteract immunosuppressants (inferred immune stimulation) and add anti-inflammatory adverse effects (Merck Manual rhodiola monograph); prescriber-led drug-level checks limit this.

Populations who should avoid Rhodiola rosea:

  • Children and adolescents under 18: European regulators restrict herbal medicines containing it to adults over 18 (EMA herbal summary).
  • Pregnancy and breastfeeding: Inferred from absent safety data and the extract’s monoaminergic activity; effects on pregnancy and passage into milk are unknown (WebMD Rhodiola monograph); no human data.
  • Bipolar disorder or history of mania: Inferred from monoamine oxidase inhibition (van Diermen 2009) and one case of mania after triple the recommended amount of R. rosea (Whig 2022); a 2018 review found no earlier Rhodiola cases (Bostock 2018); no data in bipolar disorder.
  • People on warfarin or phenytoin without monitoring: Inferred from the reduced CYP2C9 clearance shown in healthy volunteers (Thu 2016); no human data on harm in warfarin or phenytoin users.
  • Known allergy to Rhodiola or its products: Inferred from immune hypersensitivity to plant constituents; no human data on harm in this group beyond drug-reference listings of allergic reactions, which can be serious (WebMD Rhodiola monograph).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Low starting dose: common practice starts at 100–200 mg of standardized extract each morning for one week before rising toward trial doses of 340–680 mg/day (Darbinyan 2007), to limit dizziness, dry mouth and overstimulation.
  • Morning or early-day dosing: the last dose is taken before early afternoon, as in trials dosing at waking and before lunch (Cropley 2015), to prevent insomnia.
  • INR check for warfarin users: INR is rechecked 1–2 weeks after starting, changing or stopping the extract, because CYP2C9 inhibition may raise warfarin levels and bleeding risk (Thu 2016).
  • No unsupervised antidepressant combination: the extract is added to serotonergic antidepressants only with the prescriber informed and stopped at restlessness, tremor, sweating or fever, to limit serotonin-syndrome risk (Maniscalco 2015).
  • Verified products: extracts with third-party testing for identity, rosavin content and heavy metals avoid wrong-species, spiked or contaminated products (Porwollik 2026).
  • Bounded courses: courses stay within the 4–12 week durations studied, since longer-term safety is untested; European regulators advise medical advice after two weeks of continuous use (EMA herbal summary).
  • Disclosure before surgery: the surgical team is told of rhodiola use, since perioperative bleeding with platelet dysfunction occurred one week after stopping (Serna-Muñoz 2026); no source gives a pre-surgery stopping interval.
  • Stop rule for activation: stopping or halving the dose when irritability, anxiety or sleep disruption appear prevents overstimulation; no source gives a measured stopping threshold.

Therapeutic Protocol

Timing, cycling, titration steps and other parameters without a citation reflect common practice.

  • Fatigue and stress (SHR-5): 170 mg/day in physicians on night duty (Darbinyan 2000) to 576 mg/day in burnout (Olsson 2009); the extract maker sponsored these regimens.
  • Life stress (WS 1375): 200 mg twice daily, before breakfast and before lunch (Edwards 2012; Cropley 2015), the regimen popularized by Schwabe’s Vitano/Rosalin products.
  • Mild depression: 340 or 680 mg/day for 6 weeks (Darbinyan 2007); an independent trial used 340–1,360 mg/day without separation from placebo (Mao 2015).
  • Endurance exercise: 200 mg (De Bock 2004) or 3 mg/kg (Noreen 2013) one hour before exercise; in a meta-analysis, doses above 600 mg/day were associated with larger VO2max gains (Wang 2025).
  • Practitioner pre-workout use: Andrew Huberman takes 100–200 mg 10–20 minutes before high-intensity training (Huberman Lab episode); Layne Norton cites 100–600 mg, with benefit falling off above that (FoundMyFitness clip).
  • Extract standard: trial and commercial extracts are commonly standardized to about 3% rosavins and 1% salidroside (De Bock 2004; Life Extension article).
  • Time of day: morning or at the start of the waking period, with a second dose by early afternoon (Punja 2014); evening doses risk insomnia.
  • Half-life: not measured in humans; in rats intravenous salidroside has a half-life near one hour (Zhang 2013), consistent with acute effects within one hour of a dose.
  • Single versus split dosing: single morning doses suit acute exercise use; daily doses above 200–300 mg are usually split into two, as in the WS 1375 and depression trials (Darbinyan 2007).
  • Genetic polymorphisms: no variant guides dosing; CYP2C9 normal metabolizers on CYP2C9 drugs show the largest interaction (Thu 2016).
  • Sex: no sex-specific dosing data; trials enrolled both sexes, and a systematic review found sports trials enrolled mostly men (Sanz-Barrio 2023).
  • Age: trial participants were 18–70 years (Darbinyan 2007); older adults commonly start at the low end because of drug interactions.
  • Baseline biomarkers: no biomarker predicts response; trials selected people by fatigue, burnout or depression scores rather than laboratory values (Olsson 2009).
  • Pre-existing conditions: people with depression on antidepressants, or on warfarin or phenytoin, adjust or avoid use per interactions above (Thu 2016).

Discontinuation & Cycling

  • Short-term versus lifelong: studied as a short-term aid over 1 day to 12 weeks; no trial supports lifelong use, and European regulators frame it as temporary relief (EMA herbal summary).
  • Withdrawal effects: none reported in trials, including after 12 weeks of daily use (Kasper 2017).
  • Tapering: not required; stopping abruptly is usual practice. Warfarin or phenytoin users usually have a drug-level check after stopping, since the CYP2C9 inhibition shown in volunteers (Thu 2016) would be expected to wear off.
  • Cycling: four weeks of daily intake did not blunt the acute endurance effect (De Bock 2004), so tolerance is not documented; common practice still cycles 6–12 weeks on and 1–2 weeks off.

Sourcing and Quality

  • Species identity: R. rosea is often replaced or mixed with cheaper R. crenulata or other species; about one-fifth of tested products lacked rosavin, the marker specific to R. rosea (Booker 2016).
  • Standardization: standardized extracts state rosavins (about 3%) and salidroside (about 1%); US products ranged 0.01–3.08% rosavins, often far from label claims (Porwollik 2026).
  • Spiking and contaminants: one US product appeared spiked with synthetic salidroside, and all seven capsules contained trace arsenic, cobalt and lead (Porwollik 2026); third-party testing for heavy metals matters.
  • Third-party testing: USP (United States Pharmacopeia) or NSF International seals, or ConsumerLab approval (ConsumerLab review), indicate tested identity and content; the US Food and Drug Administration (FDA) does not approve supplements before sale (FDA dietary supplements Q&A).
  • Registered herbal medicines: in the EU, products registered as traditional herbal medicines were consistently authentic, unlike unregistered supplements (Booker 2016).
  • Reputable brands: the trial extracts SHR-5 (Swedish Herbal Institute, sold as Arctic Root) and WS 1375 (Schwabe, sold as Vitano and Rosalin) have the most clinical data (Olsson 2009; Edwards 2012).

Practical Considerations

  • Time to effect: acute exercise effects appear within one hour (De Bock 2004); open-label stress improvements were reported after 3 days (Edwards 2012); fatigue and mood trials ran 2–12 weeks.
  • Common pitfalls: buying unstandardized or wrong-species products, dosing in the evening, expecting a stimulant-like effect, combining several adaptogens at once, and combining with antidepressants or warfarin without telling the prescriber.
  • Regulatory status: in the US it is a dietary supplement, not approved by the FDA for safety or effectiveness before sale (FDA dietary supplements Q&A); in the EU it is a traditional herbal medicine for temporary stress symptoms (EMA herbal summary).
  • Cost and accessibility: widely available over the counter and not exceptionally expensive; it is paid out of pocket, while prescription comparators such as sertraline are reimbursed low-cost generics, so payers have no evident financial incentive shaping its research or guidance.
  • Evidence funding: most positive trials were produced or sponsored by extract makers (Swedish Herbal Institute, Schwabe), while the main independent fatigue and depression trials were null or negative (Punja 2014; Mao 2015).

Interaction with Foundational Habits

  • Sleep: Indirect and timing-dependent. Its activating profile can delay sleep if taken late, so dosing is kept to the morning; in mild depression, insomnia scores improved with treatment (Darbinyan 2007). No trial has shown it replaces sleep or offsets chronic sleep restriction.
  • Nutrition: Indirect. Fly lifespan extension depended on dietary carbohydrate and calorie content (Schriner 2016); no human food interaction is known. The acute endurance trial dosed it in the fasted state (De Bock 2004); taking it with breakfast is common practice.
  • Exercise: Potentiating for acute endurance, with lower heart rate during the warm-up and lower perceived effort during a cycling time trial (Noreen 2013); 30 days of use did not reduce marathon muscle damage (Shanely 2014). No blunting of training adaptations has been reported; acute trials dosed it one hour before exercise.
  • Stress management: Direct. In burnout, it changed the cortisol response to waking (Olsson 2009), although four weeks in healthy men did not change cortisol (Jówko 2018). It is studied as an add-on to, not a substitute for, behavioral stress reduction.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes a personal reference point. It typically includes a validated stress questionnaire and fatigue score recorded on the same day of the week and time of day and, where cortisol rhythm is of interest, saliva collected at waking and 30 minutes later. Warfarin users have a current INR, and endurance users can record a standard time trial. A one- to two-week symptom diary of sleep, energy and mood captures day-to-day variation.

Ongoing monitoring follows this cadence: questionnaires and diary at 2 weeks, 4 weeks and at the end of each course (usually 8–12 weeks); INR 1–2 weeks after starting, changing or stopping the extract; the performance test every 4–6 weeks. Success is a sustained, meaningful improvement over baseline in fatigue or stress scores without new sleep problems or side effects; absence of improvement after 4–6 weeks is commonly treated as non-response.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
INR (warfarin users only) 0.8–1.2 (standard reference range); track change from the individual’s pre-Rhodiola INR Safety check: CYP2C9 inhibition may raise warfarin effect International normalized ratio; rechecked 1–2 weeks after starting or stopping (Thu 2016); target range is set by the prescribing clinician
Perceived Stress Questionnaire or Perceived Stress Scale score No established target; track change from own baseline Expected to change: primary stress outcome in trials Used in WS 1375 studies (Kasper 2017); scores are comparable only when completed at the same time of day
Multidimensional Fatigue Inventory (MFI-20) score No established target; track change from own baseline Expected to change: fatigue outcome MFI-20 is a 20-item fatigue questionnaire used in a WS 1375 study (Edwards 2012)
Salivary cortisol awakening response No established target; track change from own baseline Expected to change: shifted with treatment in burnout Samples at waking and 30 minutes later on a workday (Olsson 2009); eating, tooth brushing or exercise before sampling distorts results
Endurance time trial or time to exhaustion No established target; track change from own baseline Expected to change: endurance outcome Same course, time of day and pre-test meal; dose taken one hour before (Noreen 2013)

Qualitative markers:

  • Afternoon energy and resistance to mental fatigue during demanding work
  • Concentration and error rate on routine tasks
  • Mood, irritability and anxiety under stress
  • Sleep onset and sleep quality (watch for worsening)
  • Perceived effort during familiar workouts

Emerging Research

  • Salidroside in in vitro fertilization: NCT06990685 is an open-label phase 2 trial in 370 older women undergoing in vitro fertilization, primary outcome ongoing pregnancy rate; not yet recruiting, completion planned 2027. A positive result would add a first reproductive-aging signal; a null result would leave the conclusion unchanged.
  • Coronary microvascular disease (disease of the heart’s smallest vessels): NCT04218916, phase 2/3, 114 patients, R. rosea capsules versus placebo, primary outcome coronary flow reserve (heart blood-flow rise under stress); completion January 2023 passed, status unknown, no results posted. A positive result would strengthen the Low cardiac item; a null result would weaken it.
  • Adult attention deficit/hyperactivity disorder: NCT02737020, 60 adults, up to 800 mg/day versus placebo; completion March 2021 passed, status unknown, no results posted. A positive result would extend attention benefits beyond fatigue; a null result would narrow them.
  • Long COVID-19 (coronavirus disease 2019) combination: NCT04795557 completed in 2021; results showed a Rhodiola-Eleutherococcus-Schisandra product shortened fatigue in some patients, in a trial co-authored by a manufacturer scientist (Karosanidze 2022). Because it tested a combination, it does not change the single-herb fatigue grade.
  • Endurance meta-analyses disagree: a 26-trial analysis found small gains (Wang 2025) and a 9-trial analysis none (Mou 2026). Larger independent trials could either confirm a small performance-enhancing effect or show it reflects publication bias (selective publishing of positive results).
  • Mammalian aging: salidroside extended lifespan in fish (Wang 2018) and across species via HSP90 (a protein-folding chaperone) inhibition (Zhang 2024), but no mouse lifespan study exists. A positive mammalian result would strengthen the longevity case; a null result would weaken it.
  • Product quality and interactions: US testing found widespread content variation and contamination (Porwollik 2026), and the CYP2C9 finding has not been tested with warfarin in people (Thu 2016). Either could shift the risk profile up or down.

Conclusion

Rhodiola rosea is a root extract from cold northern regions, used as an herb to help the body cope with stress. For health-focused adults willing to manage dose, timing and product quality, the evidence suggests, but has not independently confirmed, a modest, short-term reduction in stress-related mental fatigue, although one independent trial found the opposite, and supports a small boost to endurance when taken shortly before exercise. Benefits for mild depression and everyday stress or anxiety are possible but rest on few, small studies, some in which participants knew what they were taking, and an independent depression trial found no benefit.

The longevity case is still a laboratory story: the extract lengthens the lives of flies, worms and yeast and protects cells and rodent brains, but no study in mammals or people has tested lifespan or healthy aging directly.

Side effects in trials have been mild and reversible, at rates near or modestly above those on placebo. The main practical risks are mislabeled or contaminated products, a modest slowing of how the liver clears some medicines such as warfarin, and possible over-activation, particularly alongside antidepressants or in bipolar disorder.

The overall evidence base is small, short and of mixed quality, and much of the positive trial evidence comes from researchers linked to the companies that make the tested extracts. That pattern leaves real uncertainty about how large and how reliable the benefits are.

Top - Benefits - Risks - Protocol